cbdc campbellton- Top Featured snippets

Yin Xiyue continued to exercise the presidential power to submit the consent of the appointment of the chief justice to the National Assembly. According to the information system of the Korean National Assembly's motion, South Korean President Yin Xiyue submitted the consent of the appointment of the chief justice to the National Assembly on the 12 th, and said that "with the end of the term of office of the chief justice, in order to appoint a successor judge, the consent of the National Assembly is requested." Yin Xiyue delivered a speech to the people on the 12th, refused to end his term of office ahead of schedule, and successively approved 42 bills and enforcement orders, and also submitted a consent case for the appointment of the chief justice to continue to exercise the presidential power. According to the Korean Constitution, the Chief Justice shall be submitted by the President of the Grand Court of Korea (the High Court) and appointed by the President with the consent of the National Assembly. (CCTV News)Solar energy and other new companies have set up photovoltaic power generation equipment business. The enterprise search APP shows that recently, China Energy Saving Ledebao Solar Technology (Delingha) Co., Ltd. was established, with Du Hu as the legal representative and a registered capital of 1 million yuan. Its business scope includes: sales of solar thermal utilization equipment; Lease of photovoltaic power generation equipment; Ecological restoration and ecological protection services, etc. Enterprise investigation shows that the company is jointly owned by China Energy Saving Solar Technology Co., Ltd. and Qinghai Laidebao New Materials Co., Ltd., a wholly-owned subsidiary of solar energy.Real estate stocks fluctuated lower, with Gorgeous Family, Qixia Construction, Everbright Jiabao and Tiandiyuan falling more than 5%, while urban construction development and Chongqing development followed suit.

Trump said that he will meet with Amazon founder Bezos next week. US President-elect Trump said on Thursday that he will meet with Amazon founder Bezos next week and stressed that he will continue to contact with technology giants before returning to the White House, including those companies that have signed contracts with the US government. Trump pointed out that he had met with Meta CEO Zuckerberg earlier and had extensive contact with Tesla CEO Musk.In the exchange market, the national debt rose the most, with "National Debt 2404" rising more than 4%, "National Debt 23", "Special Country 24 03" and "Special Country 24 01" rising nearly 1%.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.

Shunkong developed 50 million yuan to set up an industrial investment company. According to the enterprise survey APP, recently, Guangdong Shunkong Qingxun Industrial Investment Co., Ltd. was established with Liang Weifeng as the legal representative and a registered capital of 50 million yuan. Its business scope includes: sales of eco-environmental materials; Sales of building materials; Sales of new membrane materials; Sales of synthetic materials, etc. Enterprise investigation shows that the company is wholly owned by Shunkong Development.Bestak: Actively deploy the C-end smart product business. At present, it has not cooperated with Bean Bag AI. Bestak said at the performance briefing on December 12 that on the one hand, the company actively deployed the C-end smart product business, exerted its own brand, promoted business expansion with category innovation, and continuously enhanced the strategic value of the new development pattern. On the other hand, the company invested in the layout of cross-border e-commerce companies, and joined hands with them to promote the series of inflator products to the sea, strengthen the cross-border e-commerce coordination strategy, and vigorously explore the potential market. In addition, the company said that the company has not cooperated with Bean Bag AI at present.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)